title: [Metastatic prostate cancer: new insights and developments].
authors.affiliation: Bereich Konservative Urologische Onkologie, Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: A
authors.initials: A
authors.lastname: Lorch
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D000069448:Denosumab; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000473:pathology* / Q000628:therapy*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy*; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000726:Androgen Antagonists; D000730:Androstadienes; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000069448:Denosumab; C552428:cabazitaxel; D000069501:Abiraterone Acetate